Better Therapeutics, Inc.
BTTX
$0.0002
$0.000.00%
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.51M | 4.79M | 5.54M | 5.27M | 5.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.34M | 7.03M | 8.93M | 8.32M | 11.00M |
| Operating Income | -5.34M | -7.03M | -8.93M | -8.32M | -11.00M |
| Income Before Tax | -5.86M | -7.59M | -9.36M | -8.76M | -11.40M |
| Income Tax Expenses | 3.00K | 1.00K | 1.00K | 4.00K | 3.00K |
| Earnings from Continuing Operations | -5.86M | -7.59M | -9.36M | -8.77M | -11.41M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.86M | -7.59M | -9.36M | -8.77M | -11.41M |
| EBIT | -5.34M | -7.03M | -8.93M | -8.32M | -11.00M |
| EBITDA | -4.50M | -6.23M | -8.17M | -8.31M | -10.30M |
| EPS Basic | -0.15 | -0.24 | -0.39 | -0.37 | -0.48 |
| Normalized Basic EPS | -0.10 | -0.15 | -0.25 | -0.23 | -0.30 |
| EPS Diluted | -0.15 | -0.24 | -0.39 | -0.37 | -0.48 |
| Normalized Diluted EPS | -0.10 | -0.15 | -0.25 | -0.23 | -0.30 |
| Average Basic Shares Outstanding | 38.50M | 31.22M | 23.83M | 23.75M | 23.69M |
| Average Diluted Shares Outstanding | 38.50M | 31.22M | 23.83M | 23.75M | 23.69M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
